La bourse est fermée
  • CAC 40

    5 598,18
    +31,39 (+0,56 %)
  • Euro Stoxx 50

    3 527,79
    +15,89 (+0,45 %)
  • Dow Jones

    29 910,37
    +37,87 (+0,13 %)

    +0,0051 (+0,43 %)
  • Gold future

    1 783,10
    -22,40 (-1,24 %)

    15 189,67
    +338,10 (+2,28 %)
  • CMC Crypto 200

    -37,24 (-10,05 %)
  • Pétrole WTI

    -0,01 (-0,02 %)
  • DAX

    13 335,68
    +208,68 (+1,59 %)
  • FTSE 100

    6 367,58
    +4,65 (+0,07 %)
  • Nasdaq

    12 205,85
    +350,85 (+2,96 %)
  • S&P 500

    3 638,35
    +8,70 (+0,24 %)
  • Nikkei 225

    26 644,71
    +107,41 (+0,40 %)

    26 894,68
    +75,28 (+0,28 %)

    -0,0029 (-0,21 %)

North America Life Science Tools Market Size, Share & Trends Analysis Report By End-use, By Technology, By Product And Segment Forecasts, 2020 - 2027

·3 min de lecture

North America Life Science Tools Market Size, Share & Trends Analysis Report By End-use, By Technology (Cell Biology, Proteomics Technologies), By Product (PCR & qPCR, Cell Biology), And Segment Forecasts, 2020 - 2027

New York, Nov. 06, 2020 (GLOBE NEWSWIRE) -- announces the release of the report "North America Life Science Tools Market Size, Share & Trends Analysis Report By End-use, By Technology, By Product And Segment Forecasts, 2020 - 2027" -

North America Life Science Tools Market Growth & Trends

The North America life science tools market size is expected to reach USD 81.9 billion by 2027 registering a CAGR of 11.6%. The market growth is attributed to a rise in government funding for life science technologies, growth of cell & gene therapies, increasing demand for biopharmaceuticals, and a rise in competition among prominent market entities.

Competitive dynamics continue to drive a rapid pace of innovation in sequencing, multiplex platforms, and major categories of mass spectrometry and liquid chromatography; this supports growth via upgrade/replacement cycles and expands the applicability of technologies. An increase in investments for R&D of life science tools is expected to drive the market significantly.

For instance, Thermofisher Scientific, one of the leading players in the market, increased its R&D expenditure by 7.32% to USD 0.264 billion year-over-year by the quarter ending June 30, 2020. A rise in the number of strategic deals & developments coupled with the steady commercial success of biopharmaceuticals is expected to accelerate market growth over the forecast period.

The Bristol-Myers Squibb/Celgene acquisition (USD 74 billion), AbbVie/Allergan acquisition (USD 63 billion), Takeda/Shire acquisition (USD 58.6 billion), Danaher and GE Biopharma M&A deal (USD 21.4 billion), Amgen / Celgene’s Otezla deal (USD 13.4 billion), and Pfizer/Array Biopharma merger (USD 11.4 billion) were some of the largest biopharma merger and acquisition deals of 2019.

North America Life Science Tools Market Report Highlights
• Cell biology technology dominated the market in 2019 owing to critical attention from key market players and academic institutions
• Continuous advancements in technologies required for analysis of cells, such as cytometry, high content analysis, and microscopy, have a great impact on the growth of cancer research, stem cell research, drug discovery, and immunology
• Moreover, these advancements have brought about high-throughput, label-free, multiplexing capabilities to cellular analysis
• Proteomics technology is anticipated to grow at the fastest CAGR from 2020 to 2027 as proteome analysis provides a complete interpretation of structural and functional information of a cell
• This, in turn, helps in the analysis of a cell’s response mechanism against a variety of foreign factors, including drugs
• PCR & qPCR is estimated to register the fastest growth rate from 2020 to 2027 owing to the upsurge in PCR adoption for Covid-19 diagnosis
• The comprehensive portfolio of cell culture media, advanced surfaces, and vessels displayed by operational entities is a result of an increase in demand for cell culture consumables among research professionals operating in the life science industry
• The rise in the adoption of genomic and proteomic workflows in hospitals to diagnose and treat several clinical abnormalities is attributed to the largest share of the healthcare end-use segment in 2019
• The U.S. market is expected to grow at a lucrative rate owing to an increase in the adoption of genomic medicines, biopharmaceuticals, and novel technologies for the diagnosis and treatment of clinical disorders
• Thermo Fisher Scientific is one of the largest suppliers of a wide range of innovative solutions for the life science community
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


CONTACT: Clare: US: (339)-368-6001 Intl: +1 339-368-6001